QP-Prostate® CAD

QP-Prostate® CAD is an AI-based image processing software designed for Computed Aided Detection and Diagnosis (CADe/CADx) of suspected prostate lesions using bi-parametric prostate MRI. It employs artificial intelligence to automatically identify and mark lesions, enhancing clinical reader performance in identifying clinically significant prostate cancer, and has demonstrated substantial equivalence to a predicate device through comprehensive performance assessments.

Quibim S.L. has developed QP-Prostate® CAD, an artificial intelligence-based image processing software designed for Computed Aided Detection and Diagnosis (CADe/CADx). This software automatically identifies and marks suspected lesions within the prostate gland using bi-parametric prostate MRI, indicating different levels of suspicion. It is intended for use by trained physicians, such as radiologists and urologists, as a concurrent aid in interpreting prostate MRI studies for patients over 40 years old, with results displayable on standard medical imaging systems. The QP-Prostate® CAD device is categorized as Class II radiological computer assisted detection/diagnosis software. It was found to be substantially equivalent to a legally marketed predicate device, ProstatIDTM, sharing similar intended uses, indications, and technological characteristics. While there are minor differences in their underlying AI algorithms and how suspicions are presented, comprehensive performance assessments, including standalone and multi-reader multi-case studies, confirmed that these differences do not raise new questions of safety or effectiveness. The studies demonstrated that the device functions as intended, enhancing clinical reader performance in identifying clinically significant prostate cancer, thus establishing its safety and effectiveness.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI algorithm in QP-Prostate® CAD specifically differ from ProstatIDTM, and what are the clinical implications of these differences?; What were the specific metrics used in the standalone and multi-reader multi-case studies to assess safety and effectiveness, particularly regarding false positives/negatives?; Are there specific MRI sequences or parameters that optimize the performance of QP-Prostate® CAD?; What is the long-term impact of using QP-Prostate® CAD on biopsy rates, overdiagnosis, and patient outcomes in a clinical setting?; Could QP-Prostate® CAD be adapted or integrated with other imaging modalities beyond bi-parametric prostate MRI for prostate cancer detection?